Journal of Biomolecular Research & Therapeutics

Abstract

Effect of Bismuth Subsalicylate on the Survival Rate of Hyperglycemic Danio Rerio

Pakhi Sahni*

More than 37 million Americans have diabetes, and approximately 90%-95% of them have Type 2 Diabetes Mellitus (T2DM). T2DM usually begins with insulin resistance, a condition in which muscle, liver, and fat cells do not use insulin well. Certain genes can also increase the likelihood of getting T2DM. Currently, metformin is one of the most common medicines used to treat this chronic condition. However, companies are recalling metformin due to the possibility the medicines could contain Nitrosodimethylamine (NDMA) above the acceptable intake limit. Not only that, but metformin is not widely accessible due to the fact that it is a prescription medicine. Evidence shows salicylates, especially salsalate, appear to be a promising alternative for prevention or treatment of diabetes by lowering glucose levels. In this study, Danio rerio were hyperglycaemically induced to model T2DM in Phase 1 Phase 2 investigated the effect of bismuth subsalicylate on decreasing blood sugar levels, and thus increasing survival rate. After statistical analysis, T2DM zebrafish with 1 mg of bismuth subsalicylate were seen to have the highest survival rate, suggesting lowest blood glucose levels, than the control group of zebrafish and other experimental groups. This study provides insight on the effectiveness of bismuth subsalicylate as a treatment for T2DM. Further studies may investigate the direct correlation between T2DM and bismuth subsalicylate using blood collection procedures with humans and more concentrations.

Published Date: 2022-08-09; Received Date: 2022-07-09